Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Telisotuzumab vedotin

Generic Name: Telisotuzumab vedotin

Drug Type: Biotech

CAS Number: 1714088-51-3

Unique Ingredient Identifier: 976X9VXC3Z

Overview

Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).

Background

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Posted: 2024/08/23

Sponsor:AbbVie

ID:NCT06568939

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Phase 3

Withdrawn

Posted: 2023/10/23

Sponsor:AbbVie

ID:NCT06093503

A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Terminated

Posted: 2022/08/24

Sponsor:AbbVie

ID:NCT05513703

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Recruiting

Posted: 2021/06/16

Sponsor:AbbVie

ID:NCT04928846

Expanded Access to Telisotuzumab Vedotin

Posted: 2021/04/05

Sponsor:AbbVie

ID:NCT04830202

FDA Approved Products

Telisotuzumab Vedotin

Manufacturer:AbbVie Inc.

Route:INTRAVENOUS

Strength:20 mg in 1 mL

Approved: 2025/05/14

NDC:0074-1044

Telisotuzumab Vedotin

Manufacturer:AbbVie Inc.

Route:INTRAVENOUS

Strength:100 mg in 1 mL

Approved: 2025/05/14

NDC:0074-1055

Singapore Approved Products

No Singapore products found for this drug

Related News

Eli Lilly Partners with Rznomics in $1.3B Deal to Develop RNA Editing Therapy for Hereditary Hearing Loss

8 days ago

Rznomics Inc. has secured a potential $1.35 billion global license option agreement with Eli Lilly to codevelop an RNA editing-based gene therapy targeting hereditary hearing loss.

Telisotuzumab Vedotin Plus Osimertinib Shows Promise in TKI-Resistant NSCLC with c-MET Overexpression

9 days ago

The combination of telisotuzumab vedotin and osimertinib demonstrated a 50% objective response rate in patients with EGFR-mutant NSCLC who had progressed after prior osimertinib treatment.

Pipeline Analysis Reveals 20+ Drug Candidates for c-MET+ NSCLC Treatment

4 months ago

DelveInsight's latest pipeline report identifies over 20 pharmaceutical companies actively developing treatments for c-MET-positive Non-Small Cell Lung Cancer, with multiple promising candidates in various clinical stages.

AbbVie's Telisotuzumab Vedotin Shows Promise in c-Met Overexpressing NSCLC

5 months ago

AbbVie's telisotuzumab vedotin (Teliso-V) demonstrated a 35% overall response rate in patients with high c-Met expression in the LUMINOSITY trial.

FDA Approves Roche's Companion Diagnostic for HER2-Ultralow Metastatic Breast Cancer

5 months ago

The FDA has approved Roche's PATHWAY HER2 (4B5) test to identify HER2-ultralow metastatic breast cancer patients for targeted treatment.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy